Meta‐analysis of the procedural risks of carotid endarterectomy and carotid artery stenting over time. BJS 2018; 105: 26-36.
Published: 4th December 2017
Authors: K. Lokuge, D. D. de Waard, A. Halliday, A. Gray, R. Bulbulia, B. Mihaylova et al.
Stroke/death rates within 30 days of carotid endarterectomy (CEA) and carotid artery stenting (CAS) in RCTs inform current clinical guidelines. However, the risks may have changed in recent years with wider use of effective stroke prevention therapies, especially statins, improved patient selection and growing operator expertise. The aim of this study was to investigate whether the procedural stroke/death risks from CEA and CAS have changed over time.
MEDLINE and Embase were searched systematically from inception to May 2016 for observational cohort studies of CEA and CAS. Studies included reported on more than 1000 patients, with 30‐day outcomes after the procedure according to patients' symptom status (recent stroke or transient ischaemic attack). Restricted maximum likelihood random‐effects and meta‐regressions methods were used to synthesize procedural stroke/death rates of CEA and CAS according to year of study recruitment completion.
Fifty‐one studies, including 223 313 patients undergoing CEA and 72 961 undergoing CAS, were reviewed. Procedural stroke/death risks of CEA decreased over time in symptomatic and asymptomatic patients. Risks were substantially lower in studies completing recruitment in 2005 or later, both in symptomatic (5·11 per cent before 2005
You may also be interested in
Authors: S. K. Kunutsor, D. Gillatt, A. W. Blom
Notes: Technology with potential
Authors: R. Mouton, C. A. Rogers, R. A. Harris, R. J. Hinchliffe
Notes: Improves 30‐day survival
Authors: H. Shiwani, P. Baxter, E. Taylor, M. A. Bailey, D. J. A. Scott
Long‐term outcomes of endovenous laser ablation and conventional surgery for great saphenous varicose veins.
Authors: T. Wallace, J. El‐Sheikha, S. Nandhra, C. Leung, A. Mohamed, A. Harwood et al.
Notes: EVLA lower recurrence at 5 years
Authors: A. J. A. Meershoek, G. J. de Borst
Predicting risk of rupture and rupture‐preventing reinterventions following endovascular abdominal aortic aneurysm repair. BJS 2018; 105: 1294-1304.
Authors: I. Grootes, J. K. Barrett, P. Ulug, F. Rohlffs, S. J. Laukontaus, R. Tulamo et al.
Notes: Potential to tailor surveillance
Open or endovascular revascularization in the treatment of acute lower limb ischaemia. BJS 2018; 105: 1598-1606.
Authors: O. Grip, A. Wanhainen, K. Michaëlsson, L. Lindhagen, M. Björck
Notes: Endovascular may save lives
Effect of aspirin in vascular surgery in patients from a randomized clinical trial (POISE‐2). BJS 2018; 105: 1591-1597.
Authors: B. M. Biccard, A. Sigamani, M. T. V. Chan, D. I. Sessler, A. Kurz, J. G. Tittley et al.
Notes: No evidence to start or stop aspirin
Authors: P. A. Coughlin, J. H. F. Rudd
Population‐based study of mortality and major amputation following lower limb revascularization. BJS 2018; 105: 1145-1154.
Authors: K. Heikkila, I. M. Loftus, D. C. Mitchell, A. S. Johal, S. Waton, D. A. Cromwell et al.
Notes: lower than previously estimated
Cost‐effectiveness of population‐based vascular disease screening and intervention in men from the Viborg Vascular (VIVA) trial. BJS 2018; 105: 1283-1293.
Authors: R. Søgaard, J. S. Lindholt
Notes: Highly cost‐effective